Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...
NYSE: PFE
Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...
Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines
Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
The US Food and Drug Administration (FDA) has accepted for priority review a filing from...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion...
AstraZeneca Acquires Icosavax to Boost Infectious Disease Pipeline with VLP Vaccine Technology
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the acquisition of US vaccines specialist...
Pfizer and CStone Secure NMPA Approval for Sugemalimab, First PD-L1 Inhibitor for ESCC
Pfizer (NYSE: PFE) and CStone Pharmaceuticals (HKG: 2616) have secured market approval from the National...
Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition
Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D
Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...
Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...